Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - promethazine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified water; calcium hydrogen phosphate; microcrystalline cellulose; isopropyl alcohol; hypromellose; macrogol 400; titanium dioxide; indigo carmine; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. ,upper respiratory tract: relief of excessive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis.,nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. ,sedation: for short term use on the advice of a doctor or pharmacist.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - promethazine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: macrogol 400; calcium hydrogen phosphate; microcrystalline cellulose; hypromellose; purified water; magnesium stearate; isopropyl alcohol; titanium dioxide; indigo carmine; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. ,upper respiratory tract: relief of excessive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis.,nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. ,sedation: for short term use on the advice of a doctor or pharmacist.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; meglumine; pregelatinised starch; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin me should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin me is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin me is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin me is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin me, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; pregelatinised starch; crospovidone; microcrystalline cellulose; meglumine; purified water; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 20.84 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; purified water; lactose monohydrate; microcrystalline cellulose; meglumine; pregelatinised starch; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 10.42 mg (equivalent: rosuvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; pregelatinised starch; meglumine; purified water; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; meglumine; lactose monohydrate; pregelatinised starch; purified water; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 41.68 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; meglumine; pregelatinised starch; microcrystalline cellulose; purified water; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mcis indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 20.84 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: meglumine; magnesium stearate; purified water; microcrystalline cellulose; lactose monohydrate; pregelatinised starch; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - rosuvastatin calcium, quantity: 5.21 mg (equivalent: rosuvastatin, qty 5 mg) - tablet, film coated - excipient ingredients: meglumine; lactose monohydrate; purified water; pregelatinised starch; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow - rosuvastatin mc should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin mc is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin mc is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin mc is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin mc, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.